Former EMA head to advise NDA Group business

Thomas Lönngren joins new European regulatory and market access business

Independent consultancy the NDA Group has launched NDA Advisory Services, a regulatory and market access business to be based in London, UK that aims to cut the rising cost of new medicines and address the challenges of drug regulation and reimbursement, to ensure that new medicines can get to patients faster.

Thomas Lönngren, previously executive director of the European Medicines Agency (EMA), will take a strategic advisory role in the new business.

The organisation said NDA’s Advisory Board would be integral integral to NDA Advisory Services and will be expanded to include HTA and market access capabilities.

New specialists are to join the Advisory Board to advise pharmaceutical companies on how they can prove the value of their products to national agencies.

Lönngren will play a fundamental role in the new business, building on 30 years’ experience in the regulatory field including the last 10 years heading EMA. One of his key ambitions is to create a co-ordinated approach to Health Technology Assessment and improve market access in Europe.

‘I’ve recognised for a long time that the whole area of market access needs new ideas and a new vision,’ he said.

‘I plan to further develop my ideas surrounding International Regulatory Strategies, coupled with pushing for a joined-up approach to HTA, to enable the best medicines to reach needy patients as efficiently as possible.’

NDA has offices in Germany, Sweden and the UK.

You may also like

Regulatory

MoonLake Immunotherapeutics faces Securities Class Action after disastrous Phase III trial results

The announcement about the trial results for the product candidate sonelokimab, a highly anticipated treatment for patients with skin disease, saw MoonLake investors' shares fall by about 90%, prompting an investigation into whether or not they were misled
Regulatory

NAD+ supplement claims under scrutiny as Niagen Bioscience wins landmark advertising case

The National Advertising Division (NAD) has ruled against Reus Research over unsupported NAD+ product claims, reinforcing that oral NAD+ ingestion lacks scientific backing and affirming Niagen’s clinically proven approach
Regulatory

Piramal Pharma Solutions awards Riverview and Digwal for patient centricity

Two sites recognised for innovative initiatives that put patients first
Manufacturing

What to expect from a regulatory inspection

NSF’s expert guide outlines key expectations, common pitfalls and strategies for lasting inspection readiness
Manufacturing

FDA US agent services backed by regulatory expertise

Helping medical device companies achieve smooth US market entry
Regulatory

FDA grants Breakthrough Therapy designation to BeOne Medicines' sonrotoclax

The designation comes after positive early results of a Phase I/II study in patients with relapsed or refractory mantle cell lymphoma, with BeOne aiming to participate in Project Orbis programme to advance global access
Regulatory

A blueprint for Digital Health Medical Technologies (DHMTs)

Understanding compliance for digital mental health technologies
Subscribe now